Literature DB >> 9865729

Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes.

C W Gregory1, K G Hamil, D Kim, S H Hall, T G Pretlow, J L Mohler, F S French.   

Abstract

The human prostate cancer (CaP) xenograft, CWR22, mimics human CaP. CWR22 grows in testosterone-stimulated nude mice, regresses after castration, and recurs after 5-6 months in the absence of testicular androgen. Like human CaP that recurs during androgen deprivation therapy, the recurrent CWR22 expresses high levels of androgen receptor (AR). Immunohistochemical, Western, and Northern blot analyses demonstrated that AR expression in the androgen-independent CWR22 is similar to AR expression in the androgen-dependent CWR22 prior to castration. Expression of prostate-specific antigen and human kallikrein-2 mRNAs, two well-characterized androgen-regulated genes in human CaP, was androgen dependent in CWR22. Despite the absence of testicular androgen, prostate-specific antigen and human kallikrein-2 mRNA levels in recurrent CWR22 were higher than the levels in regressing CWR22 tumors from 12-day castrate mice and similar to those in the androgen-stimulated CWR22. Other AR-regulated genes followed a similar pattern of expression. Differential expression screening identified androgen regulation of alpha-enolase and alpha-tubulin as well as other unknown mRNAs. Insulin-like growth factor binding protein-5, the homeobox gene Nkx 3.1, the AR coactivator ARA-70, and cell cycle genes Cdk1 and Cdk2 were androgen regulated in CWR22. In recurrent CWR22, the steady-state levels of all these AR-dependent mRNAs were similar to those in the androgen-stimulated CWR22, despite the absence of testicular androgen. Expression of AR and AR-regulated genes in the androgen-deprived recurrent CWR22 at levels similar to the androgen-stimulated CWR22 suggests that AR is transcriptionally active in recurrent CWR22. Induction of these AR-regulated genes may enhance cellular proliferation in relative androgen absence but through an AR-dependent mechanism. Alternatively, in androgen-independent tumors, induced expression of the AR-regulated gene network might result from a non-AR transcription control mechanism common to these genes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9865729

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  82 in total

1.  FHL2, a novel tissue-specific coactivator of the androgen receptor.

Authors:  J M Müller; U Isele; E Metzger; A Rempel; M Moser; A Pscherer; T Breyer; C Holubarsch; R Buettner; R Schüle
Journal:  EMBO J       Date:  2000-02-01       Impact factor: 11.598

Review 2.  Androgens and prostate cancer.

Authors:  Alan I So; Antonio Hurtado-Coll; Martin E Gleave
Journal:  World J Urol       Date:  2003-10-29       Impact factor: 4.226

Review 3.  Targeted approaches for the management of metastatic prostate cancer.

Authors:  Kathleen W Beekman; Maha Hussain
Journal:  Curr Oncol Rep       Date:  2006-05       Impact factor: 5.075

4.  The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells.

Authors:  Anthony J Saporita; Junkui Ai; Zhou Wang
Journal:  Prostate       Date:  2007-04-01       Impact factor: 4.104

5.  Androgen receptor decoy molecules block the growth of prostate cancer.

Authors:  Steven N Quayle; Nasrin R Mawji; Jun Wang; Marianne D Sadar
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-16       Impact factor: 11.205

6.  Proteomic analyses to identify novel therapeutic targets for the treatment of advanced prostate cancer.

Authors:  Barbara Comuzzi; Marianne D Sadar
Journal:  Cellscience       Date:  2006-07-27

7.  Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP.

Authors:  Adam R Karpf; Suxia Bai; Smitha R James; James L Mohler; Elizabeth M Wilson
Journal:  Mol Cancer Res       Date:  2009-04       Impact factor: 5.852

8.  Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells.

Authors:  Xin Yuan; Tong Li; Hongyun Wang; Tao Zhang; Moumita Barua; Robert A Borgesi; Glenn J Bubley; Michael L Lu; Steven P Balk
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

9.  Transcription factor KLLN inhibits tumor growth by AR suppression, induces apoptosis by TP53/TP73 stimulation in prostate carcinomas, and correlates with cellular differentiation.

Authors:  Yu Wang; Deepa Radhakrishnan; Xin He; Donna M Peehl; Charis Eng
Journal:  J Clin Endocrinol Metab       Date:  2013-02-05       Impact factor: 5.958

Review 10.  The androgen receptor in hormone-refractory prostate cancer.

Authors:  Hai-Lei Mao; Zhi-Qi Zhu; Charlie Degui Chen
Journal:  Asian J Androl       Date:  2008-12-01       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.